Latest DEF 14A proxy statements

C4 Therapeutics announces its 2026 Annual Meeting of Stockholders, set for June 24, 2026, to elect directors, vote on executive compensation, ratify auditors, and approve a plan amendment.

United Therapeutics Corporation has released its 2026 Proxy Statement, detailing proposals for the upcoming Annual Meeting of Shareholders, including director elections, executive compensation, and stock incentive plans.

Massimo Group announces its 2026 Annual Meeting of Stockholders, to be held virtually on May 27, 2026, with key proposals including director elections and executive compensation.

Sidus Space, Inc. has filed its proxy statement for the 2026 Annual Meeting of Stockholders to be held on June 18, 2026.

LM Funding America seeks shareholder approval for a reverse stock split and the issuance of shares related to 2025 financing.

TXNM Energy shareholders will vote on director elections, auditor ratification, and executive compensation ahead of the expected 2026 merger with Blackstone Infrastructure.

AST SpaceMobile, Inc. has issued its 2026 Proxy Statement detailing director elections, executive compensation, and the ratification of its independent auditor.

EWSB Bancorp, Inc. has issued its 2026 proxy statement detailing the upcoming annual meeting of stockholders scheduled for June 4, 2026.

Disc Medicine, Inc. has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation advisory votes.

Xilio Therapeutics has filed its 2026 proxy statement, seeking stockholder approval for director elections, auditor ratification, and an amendment to its 2021 Stock Incentive Plan.

Hepion Pharmaceuticals has issued its 2026 proxy statement detailing director elections, auditor ratification, and a significant expansion of its equity incentive plan.

Iovance Biotherapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 10, 2026, featuring proposals for director elections, executive compensation, and an increase in authorized common stock.

NeurAxis, Inc. has issued its 2026 proxy statement detailing proposals for director elections, auditor ratification, and significant equity plan amendments.

LM Funding America, Inc. has issued its proxy statement for the 2026 Annual Meeting, covering director elections, auditor ratification, and proposed capital structure changes.

Theravance Biopharma announces its 2026 Annual General Meeting to be held on June 12, 2026, in Dublin, Ireland.

AerSale Corporation has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026, to vote on director elections, executive compensation, and a redomestication to Texas.

Vroom, Inc. has issued its 2026 proxy statement detailing director elections, auditor ratification, and executive compensation following its 2025 emergence from Chapter 11 bankruptcy.

Bridger Aerospace Group Holdings, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, detailing proposals for director elections and auditor ratification.

Tidewater Inc. announced its 2026 Annual Meeting of Stockholders, to be held virtually on June 16, 2026, detailing director nominations, executive compensation, and stock incentive plan amendments.

Humacyte, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, to elect directors, approve executive compensation, ratify auditor selection, and vote on a significant increase in authorized shares.

Aon plc has announced its 2026 Annual General Meeting of Shareholders, scheduled for June 26, 2026, to vote on director elections, executive compensation, and auditor appointments.

Kaiser Aluminum Corporation is holding its Annual Meeting of Stockholders on June 4, 2026, to elect directors, approve executive compensation, and ratify auditor selection, while highlighting strong 2025 financial results.

OppFi Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, to vote on director elections, executive compensation, and auditor ratification.

Anika Therapeutics, Inc. has issued its proxy statement for the upcoming Annual Meeting of Stockholders on June 18, 2026, detailing proposals including director elections, auditor ratification, executive compensation approval, and amendments to equity incentive and employee stock purchase plans.

Guardant Health invites stockholders to its 2026 Annual Meeting on June 17, 2026, reporting 33% revenue growth to $982 million in 2025.

Warby Parker Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 8, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Gain Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 24, 2026, to elect directors and ratify auditor selection.

Protagonist Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing director elections, executive compensation, and equity plan proposals.

Erasca, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 26, 2026, to elect directors and ratify auditors.

Lumexa Imaging Holdings, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 10, 2026, to elect directors and ratify auditor appointment.